AMENDMENT TO THE CLAIMS
`
`The listing of claims will replace all prior versions, and listing of claims in the application.
`
`1.
`
`(Currently Amended) An oncolytic Virus comprising: (i) a GM—CSF—encoding gene; and
`
`(ii) an»inaninne-e-e—etimalater—y—pathw—a—y—-aet—irelating-melee—alennrnan a heteroiogons immune co-
`
`stimulatory pathway activating moleeuievencoding gene.
`
`2.
`
`(Previously presented) The Virus of claim l, wherein the immune eovstimula'tnry pathway
`
`activating molecule-encoding gene encodes C1140 ligand (ClMlll_.), {€03 ligand, GETR ligand,
`
`4-—l--BB ligand, OXAA) ligand, ’l‘LlA, CD30 ligand, CD27 or flt3 ligand.
`
`3.
`
`(Currently Amended) The Virus of claim l, wherein the immune co--stimnlatory pathway
`
`activating molecnle-enending gene encodes an agonist oi CD40, lCOS, GETR, 4—l-BE, 0X40 nr
`
`lltll, optienally C1340 ligand, Gilli ligand, 4-1433 ligand, (1X40 ligand, 9: ECUS ligand.
`
`4.
`
`(Original) The Virus of claim l, wherein the immune cit—stimulatory pathway activating
`
`mnleeule—eneoding gene encodes a CTLA~4 inhibitor.
`
`5.
`
`(Original) The Virus of claim 4, wherein the C'l‘LA--4 inhibitor is a Cl‘lJ’X-élL antibody or
`
`fragment thereof.
`
`6.
`
`(Previously presented) The Virus of claim l, further comprising a fusogenic protein~
`
`encoding gene.
`
`7.
`
`(Currently Amended) The Virus of claim 6 where the t‘nsogenic protein is selected from
`
`the group consisting of vesicular stomatitis Virus (VSV) G-protein, syncitin--l, syncitin-Q, simian
`
`Virus 5 (8V5) F-prntein, measles virus (MV) Til—protein, MV F—protein, respiratory syneytial
`
`Virus (RSV) F-protein and a glycoprotein from gihhon ape leukemia Virus (GALV), murine
`
`988741291
`
`— 2 —
`
`
`
`leukemia virus (MLV), Mason-Pfizer irionliey virus (MPMV) or and equine infectious anaemia
`
`virus (ElAV) trorn which the R peptide has been deleted.
`
`8.
`
`(Previously presented) The virus of claim 6, wherein the t’usogenic protein is the
`
`glycoprotein from gibbon ape leukemia virus (GALV) and has the R transniemhrane peptide
`
`mutated or removed (GALV—R~),
`
`9,
`
`(Previously presented) The virus of claim l, which encodes more than one immune co—
`
`stimnlatory pathwa y activatin g molecule.
`
`ll).
`
`(Previously presented) The virus of claim l, which is derived from a clinical isolate of a
`
`virus,
`
`ll.
`
`(Previously presented) The virus of claim l, which is a modified clinical isolate of a
`
`virus, wherein the clinical isolate kills two or more tumor cell lines more rapidly and/or at a
`
`lower dose in viz/'0 than one or rnore reference clinical isolates of the same species of virus.
`
`l2,
`
`("Previously presented) The virus of claim ll), wherein the clinical isolate is
`
`strain RHOlSA having the accession number ECCAC l612l904;
`
`strain RHOMA having the accession number ECC AC l6l2l902;
`
`strain RHG31A having the accession number ECCAC l6121907;
`
`strain REM-QB having the accession number ECCAC l6l2l908;
`
`strain RHOlSA having the accession number ECCAC l612i903;
`
`strain RHOZlA having the accession number ECCAC l612l905;
`
`strain Rl-lGZClA having the accession number ECCAC ltil2l906; or
`
`strain RH047A having the accession number ECCAC 16121909.
`
`l3.
`
`(Previously presented) The virus of claim l, which is selected from the group consisting
`
`of herpes viruses, pox viruses, adenoviruses, retroviruses, rhabdoviruses, paramyxoviruses and
`
`reoviruses.
`
`l4.
`
`(Previously presented) The virus of claim l, which is a herpes simplex virus (HS V).
`
`988741291
`
`_ 3 _
`
`
`
`15.
`
`16.
`
`I,1.
`
`:i
`
`(Qifiginai) The virus (if claim 14 which is a HSVT.
`
`(Original) The Virus of claim, 15, wi'iereih the i-ESV:
`
`(a) does not express functional TCP345;
`
`(b) does not express functional TCP47; and/er
`
`(c) expresses the US$11 gene as an immediate eariy gene.
`
`(Previeusiy presented) The virus (if claim, 14, wherein the GM—CSF—ehcedihg gene and
`
`an immune ce--stimuiatery pathway activating n10i€cui€--€l‘1€0difl
`
`g gene are inserted into the
`
`iCPEir-i-fi encnthng teens. either by h’isertinn, er partial or cehipiete deletion, in a hack. tn hack
`
`Orientation in reiatien t0 each other, each under separate reguiatory central.
`
`18.
`
`(Previeusiy presented) The Virus of claim 3, wherein the sequence cf 21 gene enceding
`
`(EM—CS}? and/or the sequence at the gene enceding an ce—irnrnunc stiinuiatery pathway
`
`activating meiecuie is coden optimized so as to increase expressien ieveis in target cells.
`
`19.
`
`(Cancel)
`
`2Q.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`(C ancei)
`
`(Cancel)
`
`(Cancel)
`
`(Cancel)
`
`(Cancei)
`
`(Cancei)
`
`(Cancei)
`
`988741291
`
`— 4 —
`
`
`
`27.
`
`(Previously presented) A pharniaceutieai composition conipri sing the virus of claim 1
`
`and a pharrnaceutieaiiy acceptable carrier or dihient,
`
`28. — 37. (Canceiied)
`
`2:8.
`
`("Previously presented) A product of manufacture comprising a virus according to ciaiin
`
`1 in a steriie viai, arnpouie or syringe.
`
`39.
`
`(Previously presented) A method of treating cancer, which comprises administering a
`
`therapeuticaiiy effective amount of the. virus of ciairn i to a patient in need thereof,
`
`40.
`
`(Previousiy presented) The method of ciairn 3.9, which further comprises administering a
`
`therapeuticaiiy et" Tective amount of a further anti-cancer agent to a patient in need thereof.
`
`41.
`
`(Previously presented) The method of claim 40, wherein the further anti-cancer agent is
`
`selected from the group consisting of an agent targeting an inunune (to—inhibitory or immune co—
`
`stirnuiatory pathway, radiation and/or chemotherapy, an agent that targets a specific genetic
`
`mutation which occurs in turnors, an agent intended to induce an irnrnune response to one or
`
`more turnor antigents) or neoantigents), a ceiiuiar product derived from T cells or NK ceiis, an
`
`agent intended to stiinniate the STING, cGAS, TLR or other innate immune response and/or
`
`it’lii?tfilti‘tht0fy pathway, a second virus optionally an oncoiytic virus, and combinations thereof.
`
`4-2.
`
`(Previously presented) The method of ciairn 4-1, wherein the agent targeting an inunune
`
`co--inhibitory pathway is a C’i‘LA—d inhibitor, a FED-i inhibitor, a PD-Li inhibitor, a LAG-3
`
`inhibitor, a TIE/iv}: inhibitor, a VISTA inhibitor, aCSFiR inhibitor, an H30 inhibitor, a KER
`
`inhibitor, a SLAMF? inhibitor, a CEACAMi inhibitor or a C947 inhibitor, and/or the agent
`
`targeting an irnrnune (so—stimulatory pathx 'ay is a GITR agonist, a did—BB agonist, an 0X40
`
`agonist, a (31340 agoni st or an BEDS agonist.
`
`43.
`
`(Previously presented) The method of claim 4i, wherein the. further anti—cancer agent
`
`comprises an antibody.
`
`988741291
`
`_ 5 _
`
`
`
`44.
`
`(Previously pi‘csciiicd) The methcd 0f ciaim 4G, whcrein the Virus and the further anti--
`
`cancer agema’S) are. adminisici‘cd scparaiciy.
`
`45.
`
`(Prcviuusiy prescnted) The mcihud 03? claim 40, wherciri the. virus and the. further ami—
`
`cancer agcnfis) are administered ci‘mcurrcmiy.
`
`46.
`
`("Prcvicusly pmmntcd) The: mathcd of claim 40, whci‘ein thc cancer is, a. sciid tumor.
`
`47. — 48. (Cancelled)
`
`988741291
`
`_ 6 _
`
`
